论文部分内容阅读
本文对60例正常人和53例充血性心力衰竭患者体内安替比林处置进行了研究。利用高效液相色谱法测定正常人和心衰患者血浆安替比林浓度。根据DΦssing一次样本测定安替比林清除率的方法计算安替比林半衰期及清除率,同时进行心功能测定。11例心衰患者进行了治疗前后血浆安替比林浓度测定。结果表明:正常人组安替比林半衰期15.3±3.2h,清除率25.7±3.81ml/min;心衰组安替比林半衰期29±8.6h清除率12.8±3ml/min。心衰患者的安替比林半衰期和清除率与正常人比较有极显著差异(p<0.001)心衰患者安替比林清除较正常人明显减慢。心衰程度愈重,安替比林清除愈慢。且与心功能指标CO,TPR,肝功能A/G场比值显著相关。提示心衰患者体内安替比林处置存在明显障碍。表明心衰时肝脏药物氧化功能降低。
This article studied the treatment of antipyrine in 60 normal subjects and 53 patients with congestive heart failure. Determination of plasma antipyrine concentration in normal and heart failure patients by high performance liquid chromatography. According to DΦssing a sample determination of antipyrine clearance rate calculation of antipyretic half-life and clearance, at the same time the determination of cardiac function. Eleven patients with heart failure before and after treatment were measured plasma antipyrine concentration. The results showed that the half-life of antipyrine in normal subjects was 15.3 ± 3.2 h and the clearance rate was 25.7 ± 3.81 ml / min. The half-life of antipyrine in 29 ± 8.6 h was 12.8 ± 3 ml / min. In patients with heart failure, the half-life and clearance rates of antipyrine were significantly different from those of normal subjects (p <0.001). Antipyrine clearance was significantly slower in patients with heart failure than in normal subjects. The more severe heart failure, antipyrine slower removal. And with cardiac function index CO, TPR, liver function A / G ratio was significantly correlated. There is a clear barrier to antipyrine treatment in patients with heart failure. That heart failure, liver drug oxidation decreased.